Stay Ahead of Wall Street. Find out what is happening to Flexion Therapeutics, Inc. (NASDAQ:FLXN) stock today? Its price is nose-diving -1.01 points, trading at $16.11 levels, and is down -5.87% from its previous close of $17.12. The shares seem to have an active trading volume day with a reported 450527 contracts so far this session. FLXN shares had a relatively better volume day versus average trading capacity of 600.32 thousand shares, but with a 36.45 million float and a -0.29% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for FLXN stock indicates that the average analyst price target is $26.38 per share. This means the stock has a potential increase of 63.75% from where the FLXN share price has been trading recently which is between $16.46 and $17.18. There are some brokerage firms that offer lower targets than the average, with one of them, even setting their price target at $19. Flipping the other side of the coin, an analyst who is fully bullish set a price target as high as $36.
During the recent trading session for Flexion Therapeutics, Inc. (NASDAQ:FLXN), the company witnessed their stock drop by $-1.21 over a week and surge $2.83 from the price 20 days ago. When compared to their established 52-week high of $17.82, the high they recorded in their recent session happens to be lower. Their established 52-week high was attained by the company on 04/11/19. The recent low of $8.76 stood for a -10.47% since 05/08/19, a data which is good for most investors who are looking to take advantage of the stock’s recent rise. A beta of 1.36 is also allocated to the stock. Since the beta is greater than one, it implies that the stock is more volatile than the market, a data that traders are keeping close attention to. At the moment, the median target price for FLXN is set at $27, a figure which is above the recent 1-year high the stock witnessed.
Looking at the current readings for Flexion Therapeutics, Inc., the two-week RSI stands at 54.74. This figure suggests that FLXN stock, for now, is neutral, meaning that the shares are stable in terms of price movement. The stochastic readings, on the other hand, based on the current FLXN readings is similarly very revealing as it has a stochastic reading of 67.77% at this stage. This figure means that FLXN share price today is being neutral.
Technical chart claims that Flexion Therapeutics, Inc. (FLXN) would settle between $17.38/share to $17.64/share level. However, if the stock price goes below the $16.66 mark, then the market for Flexion Therapeutics, Inc. becomes much weaker. If that happens, the stock price might even plunge as low as $16.2 for its downside target. The stock is currently in the red zone of MACD, with the indicator reading -0.19. Traders are always alerted for the move of a stock above or below the zero line due to the fact that the reading is an indicator of the position of the short-term average relative to the long-term average. If the MACD is above the zero line, then the short-term average relative is above that of the long-term average, thus implying an upward momentum. Vice versa is the case if the MACD is below the zero line.
Analysts at The Benchmark Company raised their recommendation on shares of FLXN from Hold to Buy in their opinion released on May 09. Needham analysts again handed out a Buy recommendation to Flexion Therapeutics, Inc. (NASDAQ:FLXN) stock but they lifted target price for the shares in a flash note issued to investors on January 04. The target price has been raised from $42 to $36. Analysts at The Benchmark Company lowered the stock to a Hold call from its previous Buy recommendation, in a research note that dated back to January 04.
FLXN equity has an average rating of 1.8, with the figure leaning towards a bullish end. 8 analysts who tracked the company were contacted by Reuters. Amongst them, 0 rated the stock as a hold while the remaining 8 were split even though not equally. Some analysts rate the stock as a buy or a strong buy while no rated it as a sell. 8 analysts rated Flexion Therapeutics, Inc. (NASDAQ:FLXN) as a buy or a strong buy while not a single analyst advised that investors should desist from purchasing the stock or sell them if they already own the company’s stock.
Flexion Therapeutics, Inc. (FLXN)’s current-quarter revenues are projected to climb by nearly 151.9% to hit $24.04 million, based on current consensus estimate. The firm’s full-year revenues are expected to expand by over 211.4% from $22.52 million to a noteworthy $70.13 million. At the other end of the current quarter income statement, Flexion Therapeutics, Inc. is expected to see its adjusted earnings surge by roughly 15.9% to hit $-0.9 per share. For the fiscal year, FLXN’s earnings are projected to climb by roughly 12.9% to hit $-3.91 per share.